




>>Entry Name: Ondansetron, BAN, INN

Synonym(s): 1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1*H*-imidazol-1-yl)methyl]-4*H*-carbazol-4-one, 9Cl



CAS Registry Number: 116002-70-1

Related CAS Registry Numbers(s): 99614-58-1 99614-60-5

Molecular Formula: C₁₈H₁₉N₃O

Molecular Weight: 293.368

Accurate Mass: 293.152812

Percentage Composition: C 73.70%; H 6.53%; N 14.32%; O 5.45%

Biological Use/Importance: 5HT₃-receptor antagonist; antiemetic used to control nausea induced by cancer chemotherapy

Development Status: Marketed drug. Launched 1990. Worldwide 62nd best selling prescription drug (\$0.74 bn) (GlaxoSmithKline) (2000, Pharma Business)

Calculated Log P Data: Log P 2.64 (calc)

>>Variant: (±)-form

Synonym(s): GR 38032

CAS Registry Number: 99614-02-5

Molecular Formula: C₁₈H₁₉N₃O

Molecular Weight: 293.368

Accurate Mass: 293.152812

Percentage Composition: C 73.70%; H 6.53%; N 14.32%; O 5.45%

Sigma: O4136

>>Derivative: Hydrochloride

Synonym(s): Ondansetron hydrochloride, BAN. Fixca. Helmine. Yatrox. Zofran. Zophren

CAS Registry Number: 103639-04-9

Extra CAS Registry Numbers(s): 99614-01-4

Physical Description: Cryst. (EtOH)

Melting Point: Mp 186-187° (monohydrate)

References:

- Ger. Pat.*, 1985, 3 502 508; *CA*, **104**, 19589, (*synth, pharmacol*)
Stables, R. *et al.*, *Cancer Treat. Rep.*, 1987, **14**, 333, (*pharmacol*)
Hagan, R.M. *et al.*, *Eur. J. Pharmacol.*, 1987, **138**, 303, (*pharmacol*)
Milne, R.J. *et al.*, *Drugs*, 1991, **41**, 574, (*rev*)
Kawakira, T. *et al.*, *Chem. Pharm. Bull.*, 1992, **40**, 624, (*pharmacol*)
Oxford, A.W. *et al.*, *Prog. Med. Chem.*, 1992, **29**, 239, (*rev*)
Tyers, M.B., *Semin. Oncol.*, 1992, **19**, 1; 9; 53, (*rev*)
Butcher, M.E., *Oncology*, 1993, **50**, 191, (*use, rev*)
Mohan, K.C. *et al.*, *Acta Cryst. C*, 1995, **51**, 2627, (*cryst struct, hydrochloride*)
Wilde, M.I. *et al.*, *Drugs*, 1996, **52**, 773-794, (*rev*)
Martindale, The Extra Pharmacopoeia, 32nd edn., *Pharmaceutical Press*, 1999, 1206